Alto Neuroscience, Inc. (ANRO) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Alto Neuroscience is a clinical-stage biopharmaceutical company focused on developing personalized treatments for psychiatric disorders (MDD, BPD, TRD, schizophrenia, Parkinson's) using its Precision Psychiatry Platform. The company has no product revenue and relies on equity financings and debt to fund operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(26.2) million | $(15.2) million |
| Operating Expenses | $27.1 million | $15.7 million |
| Research & Development | $20.3 million | $10.0 million |
| General & Administrative | $6.8 million | $5.7 million |
| Cash & Equivalents (End of Period) | $263.8 million | $176.5 million |
| Net Cash Used in Operating Activities | $(27.1) million | $(16.6) million |
| Net Cash Provided by Financing | $114.9 million | $9.1 million |
| Debt (Term Loan Principal) | $15.0 million | $16.0 million |
Note: The company reported an accumulated deficit of $227.9 million as of March 31, 2026.
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss increased by $11.1 million (73%) compared to Q1 2025, driven primarily by a $10.3 million increase in R&D expenses.
- R&D Drivers: Significant spending increases were attributed to the ALTO-101 program ($4.4M increase) and the newly acquired ALTO-207 program ($4.1M increase) to support Phase 2b trial initiation.
- Capital Raise: The company completed a private placement in March 2026, raising approximately $120.0 million in gross proceeds ($114.9 million net), significantly boosting liquidity compared to the prior year.
- Debt Conversion: K2 HealthVentures LLC converted $1.0 million of outstanding loan balance into common stock during the quarter.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash ($263.8 million) plus anticipated proceeds from the Wellcome Trust Convertible Grant Agreement will fund operations for at least the next 12 months.
- Clinical Milestones:
- ALTO-207: Phase 2b trial for Treatment Resistant Depression (TRD) initiated in April 2026; topline data expected H2 2027.
- ALTO-300: Phase 2b trial for MDD ongoing; topline data expected H1 2027.
- ALTO-100: Phase 2b trial for Bipolar Depression ongoing; topline data expected mid-2027.
- ALTO-101: Phase 2 proof-of-concept for schizophrenia cognitive impairment did not meet primary endpoints but showed directional improvements in EEG measures; modified-release formulation being explored.
- Risks & Contingencies:
- Legal Proceedings: A putative securities class action lawsuit was filed in July 2025 regarding the 2024 IPO disclosures. The company filed a motion to dismiss in May 2026 and believes the allegations lack merit.
- Debt Covenants: The Amended Loan Agreement requires maintaining a cash runway of at least 5 months (waived if market cap exceeds $700 million).
- Profitability: No assurance the company will ever be profitable; continued capital raises will be necessary.
Investor Verification Checklist
- Cash Runway: Verify the 12-month liquidity projection against current burn rates and potential delays in clinical milestones.
- ALTO-101 Data: Review the detailed analysis of the Phase 2 POC trial results to assess the viability of the modified-release formulation strategy.
- Legal Exposure: Monitor the status of the securities class action lawsuit and potential settlement costs or diversion of management resources.
- Dilution: Assess the impact of the March 2026 private placement (2.9M shares + 3.1M pre-funded warrants) and existing warrant/option overhang on future share count.
- Debt Terms: Confirm compliance with the 5-month cash runway covenant and review the exit fee obligations (5.95% of funded amount) on the K2 term loan.